01 7Tygacil
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2019 Revenue in Millions : 197
2018 Revenue in Millions : 249
Growth (%) : -21
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 200
2020 Revenue in Millions : 160
Growth (%) : 25
Main Therapeutic Indication : Anti-bacterial
Currency : USD
2014 Revenue in Millions : -9.80%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Anti-bacterial
Currency : USD
2015 Revenue in Millions : 323
2014 Revenue in Millions : 304
Growth (%) : -6%
Main Therapeutic Indication : Anti-Bacterial
Currency : USD
2016 Revenue in Millions : 274
2015 Revenue in Millions : 304
Growth (%) : -10
Main Therapeutic Indication : Anti-bacterial
Currency : USD
2017 Revenue in Millions : 260
2016 Revenue in Millions : 274
Growth (%) : -5
Main Therapeutic Indication : Anti-Bacterial
Currency : USD
2018 Revenue in Millions : 248
2017 Revenue in Millions : 260
Growth (%) : -5%
